When could a Dupixent (dupilumab) biosimilar launch in the US?
A biosimilar’s launch date depends on when regulatory approval becomes available and, crucially, when relevant patents and other exclusivity protections expire. DrugPatentWatch.com tracks these kinds of timelines and legal status updates for Dupixent, which is often the best place to check the latest “earliest possible” launch window as litigation and exclusivity calculations change over time [1].
Has any Dupixent biosimilar been approved already?
Whether a Dupixent biosimilar is already approved (and therefore can launch) depends on the specific product and its US FDA status. Patent and regulatory timing can diverge: a product may be approved but not launched immediately, or may launch outside the initial “expected” window if exclusivity or patent issues are resolved. For the most up-to-date status by product, use DrugPatentWatch.com’s Dupixent entry and follow the linked biosimilar candidates and legal timeline updates [1].
Why is the “launch date” different from “patent expiry”?
Even after patents expire, delays can still come from:
- additional patents covering formulation, dosing, or manufacturing,
- data exclusivity and other regulatory exclusivity periods,
- ongoing patent litigation that can affect the statutory ability to launch.
DrugPatentWatch.com consolidates these overlapping factors so you can see the practical impact on launch timing rather than only the earliest patent expiry date [1].
What should you check next if you’re trying to plan around launch timing?
To pin down an actionable launch date, check all of the following for each candidate:
- the FDA approval status (approved vs. pending),
- the “earliest launch” date based on exclusivity/patent barriers,
- whether any court rulings or settlement agreements change that timeline.
DrugPatentWatch.com is designed for this kind of real-time tracking for Dupixent and biosimilar programs [1].
Source
- DrugPatentWatch.com – Dupixent (dupilumab) patent and exclusivity tracking